The global gene synthesis market is currently experiencing one of the most dynamic growth phases in the biotechnology sector. In 2023, the gene synthesis market was valued at USD 2,245.5 million. Projections indicate that it will grow to USD 2,736.81 million in 2024, and further surge to USD 12,204.87 million by 2031, exhibiting a compound annual growth rate (CAGR) of 23.81 % during the forecast period. This strong upward trajectory underscores the escalating demand for synthetic DNA technologies across research, therapeutic, and industrial biotechnology domains.
Market Overview
Gene synthesis refers to the artificial, de novo construction of DNA sequences in the laboratory, assembling nucleotides according to a designed sequence rather than relying on natural templates. This capability enables scientists to create novel genes, engineer genetic circuits, optimize codon usage, and design synthetic biology systems tailored to specific functions. Gene synthesis plays a foundational role in modern molecular biology, synthetic biology, gene editing, vaccine development, functional genomics, and protein engineering.
The market splits broadly into two categories: gene synthesis products (e.g. reagents, enzymes, oligo building blocks, synthesis instruments) and gene synthesis services (custom gene assembly, DNA fragment delivery, library synthesis). Over time, services tend to dominate revenue as many end users outsource the capital-intensive and technically demanding synthesis steps, while the product side supports those services as well as in-house users.
The growth of the gene synthesis market is closely tied to trends in genomics, synthetic biology, personalized medicine, CRISPR gene editing, and vaccine/therapeutics R&D. As these upstream fields expand and diversify, demand for reliable, high-throughput gene synthesis increases accordingly. The value proposition of gene synthesis lies in speed, precision, flexibility (creating sequences not found in nature), and enabling rapid iteration in biological design.
In context, the market’s more than fivefold increase (from ~USD 2,245.5 million to USD 12,204.87 million) over the forecast period reflects both higher average pricing of sophisticated synthesis offerings and significant volume expansion into new application domains.
Trends
Several key trends are shaping the gene synthesis market:
High-throughput and automation advances
Automation, robotics, microfluidics, and parallelization are enabling gene synthesis at much higher scale and lower cost. Platforms that can synthesize hundreds or thousands of fragments in parallel are becoming more common, reducing lead time and unit cost.Error correction and fidelity enhancement
One of the technical challenges in gene synthesis is sequence errors. Improved error-correction enzymes, post-assembly proofreading, and high-fidelity synthesis chemistries are increasingly built into synthesis workflows, boosting reliability and lowering downstream failure risk.Enzymatic DNA synthesis (next-gen / template-free approaches)
An emerging shift is the development of enzymatic (rather than chemical) synthesis methods that promise longer continuous sequences, lower waste, and perhaps simpler workflows. These next-generation approaches may disrupt conventional phosphoramidite chemistry in the medium to long term.AI / algorithmic design and sequence optimization
Genetic sequence design is becoming more intelligent: AI and machine learning models are being used to optimize codon usage, reduce secondary structure, predict expression, and flag off-target effects. These design tools are tightly integrated with synthesis pipelines.Modular / library synthesis and multiplexing
Beyond making one gene, synthesis providers are offering library construction, variant libraries, multiplexed gene pools, and barcoded constructs — especially valuable in synthetic biology, directed evolution, screening, and combinatorial engineering.Integration with gene editing, synthetic biology, and cell engineering workflows
Gene synthesis is no longer a standalone service but a component in a broader suite: plasmid assembly, CRISPR guide design, cell line engineering, metabolic pathway construction, and systems biology loops.Cost reduction and democratization
As platforms mature, per-base synthesis costs continue declining. This opens access to smaller labs, startups, and nontraditional application areas (agriculture, industrial biotech, biomanufacturing).Regulation, biosafety, and biosecurity awareness
With capabilities to fabricate genes, the field faces scrutiny around dual-use risk, biosecurity, and oversight. Providers and regulators are increasingly embedding screening protocols, sequence vetting, and ethical policies into their operations.
Demand
The demand for gene synthesis arises from multiple converging forces:
Rise of synthetic biology and engineering biology
As synthetic biology expands into industrial bioproducts, biofuels, engineered microbes, agricultural traits, and biosensors, the need to design and build novel genes or pathways is foundational.Growth in gene therapy, cell therapy, and personalized medicine
Custom gene constructs, viral vectors, and engineered cell therapies depend on synthetic DNA. As more gene therapies advance to clinical and commercial stages, demand for high-quality gene synthesis will surge.Vaccine development, diagnostics, and infectious disease research
The COVID-19 pandemic highlighted how rapidly gene synthesis underpins vaccine antigen design, viral gene constructs, diagnostic probes, and vaccine libraries. This experience reinforces the strategic importance of fast, dependable gene synthesis.Functional genomics, systems biology, and basic research
Academic and research institutions increasingly use synthetic genes to test hypotheses, build genetic circuits, and perform multiplexed perturbations, driving steady demand for synthesis services and supporting products.Protein engineering and directed evolution
Engineering novel enzymes, therapeutic proteins, or biocatalysts requires synthetic genes and variant libraries. The ability to customize sequences accelerates optimization cycles.Agricultural biotechnology and synthetic agrigenomics
Crop trait engineering, synthetic promoters, gene stacks, and editing constructs are growing markets, particularly in countries investing in next-gen agri innovations.Industrial biotechnology and metabolic engineering
Synthetic pathways for chemicals, bio-based materials, or specialty compounds require gene constructs and synthetic operons assembled for expression in microbial hosts.
Overall, demand is broadening in both the depth (more complex constructs, larger libraries) and breadth (more industries adopting gene-based engineering) dimensions.
Dynamics (Drivers, Restraints, Opportunities, Challenges)
The gene synthesis market is subject to dynamic forces that both enable and constrain its growth.
Drivers / Growth Enablers
Continuous investment in biotechnology research and development
Decreasing cost per base of DNA synthesis
Increased throughput and reliability of synthesis platforms
Strong pipeline growth in gene therapies, synthetic biology, and advanced therapeutics
Government funding, grants, and favorable policies for genomics and biomanufacturing
Growing adoption in emerging markets and broader industrial applications
Partnerships and business models bundling design, synthesis, and biology services
Restraints / Challenges
High cost and risk for long or highly complex gene constructs
Technical limitations including error rates, sequence constraints, secondary structure, GC content extremes
Intellectual property issues (patents on sequences, synthesis techniques)
Regulatory, ethical, and biosecurity oversight that may slow or restrict certain uses
Lack of skilled personnel in some geographies
Competition from smaller local synthesis providers, which may limit margins for global players
Reaction time and logistics — shipping, customs, lead times can hamper user adoption in remote regions
Opportunities
Adoption of enzymatic synthesis technologies that reduce waste and enable longer constructs
Offering integrated workflows (design → synthesis → assembly → validation) as end-to-end service
Expansion into nontraditional sectors (agro, industrial biotech, environmental DNA engineering)
Platform licensing, SaaS design tools, and library marketplaces
Geographic expansion into fast-growing biotech hubs in Asia, Latin America, and Africa
Performance-based or subscription business models (e.g., pay-per-use, library-as-a-service)
Challenges to Overcome
Ensuring high fidelity across ever-larger constructs
Maintaining cost, scalability, and throughput while pushing complexity
Establishing standards for sequence screening, authentication, and biosafety
Handling IP/licensing complexities around certain gene elements
Achieving regulatory clarity in diverse jurisdictions
Future Outlooks
Given the projected CAGR of 23.81 % from 2024 to 2031 (and the forecast to reach USD 12,204.87 million by 2031), the gene synthesis market is expected to transform considerably over the coming decade. Key future trajectories are:
Mainstreaming of enzymatic and next-generation synthesis
Chemical synthesis may gradually cede some territory to enzymatic and template-free methods that offer continuous strand extension, lower waste, and scalability. These approaches may become increasingly commercial within the forecast window.Seamless design-to-build platforms
The future will see fully automated pipelines where user-friendly design portals feed directly into synthesis, error correction, QA, and assembly. Turnaround time may shrink to hours or a few days even for complex constructs.Library marketplaces & gene economies
Synthetic gene “shops” may evolve into on-demand marketplaces offering off-the-shelf or variant libraries, modular genetic parts, and community-shared designs.Increasing adoption in industrial and agricultural biotech
While much current demand is in life sciences and pharma, gene synthesis will progressively infiltrate industrial biotech, agriculture, environmental biotech, and microbial manufacturing as costs drop and reliability improves.Outcome-based offerings and synthetic biology-as-a-service
Vendors may shift toward models that charge based on successful expression, throughput, or functional yield rather than pure synthesis services. Bundled service contracts may become standard.Stronger regulation, oversight, and standardization
As the ability to construct genes becomes more ubiquitous, regulatory agencies and industry consortia will implement tighter screening, monitoring, and ethical oversight practices. Vendors will adopt best practices for sequence vetting, antibiosecurity, and transparent audit trails.Widening geographic penetration and democratization
As costs decline and platforms decentralize, more labs in developing economies will access gene synthesis. Regional hubs, local manufacturing, and partnerships will expand reach.
By 2031, the market is likely to be more mature, with diversified end users, more fierce competition, and a shift toward integrated biology platforms rather than isolated synthesis offerings. The players that combine technical excellence, design tools, business model innovation, and geographic reach will lead the pack.
Market Key Players
The gene synthesis market is competitive and features several prominent global players, mid-sized specialists, and numerous niche providers. Some of the leading names include:
Thermo Fisher Scientific, Inc.
Twist Bioscience
Boster Biological Technology
Biomatik
OriGene Technologies, Inc.
Azenta (GENEWIZ)
Merck KGaA
Evonetix
Integrated DNA Technologies (IDT)
ProMab Biotechnologies
Brooks Automation (via GENEWIZ)
Eurofins Genomics
GenScript
ProteoGenix
These players compete on technology (fidelity, speed, error correction), throughput, cost, geographic presence, service breadth, and integration of design-to-build pipelines. Many engage in partnerships, mergers, acquisitions, platform licensing, and collaborations with biotech or pharma firms to advance capabilities and expand market reach.
For example, some companies are actively developing enzymatic DNA synthesis platforms, investing in AI design tools, or acquiring smaller local providers to strengthen regional footprint. Strategic collaborations between synthetic biology firms and synthesis providers are also becoming more common, as users seek end-to-end solutions.
Market Segmentation
The gene synthesis market can be segmented across multiple dimensions:
By Type / Offering
Gene synthesis products (reagents, enzymes, oligos, synthesis instruments)
Gene synthesis services (custom gene synthesis, library synthesis, variant constructs, sequence validation services)
By Methodology / Technology
Solid-phase chemical synthesis
PCR-based enzyme synthesis
Chip-based DNA synthesis (microarray-derived)
Emerging / enzymatic / template-free synthesis
By Application
Gene and cell therapy development
Vaccine development
Functional genomics / synthetic biology research
Protein production / enzyme engineering
Disease diagnosis / diagnostics
Academic & industrial research
Others
By End User
Biopharmaceutical & biotech companies
Contract research organizations (CROs)
Academic and government research institutes
Gene editing / synthetic biology companies
Diagnostic labs / companion diagnostics
By Region
North America (U.S., Canada, Mexico)
Europe (UK, Germany, France, Italy, Russia, Rest of Europe)
Asia Pacific (China, Japan, India, South Korea, Rest of APAC)
Latin America (Brazil, Argentina, Rest)
Middle East & Africa
In many analyses, the service side commands the larger share due to higher value added and outsourcing preference. Among methods, solid-phase chemical synthesis typically holds a dominant share currently, though newer techniques may grow faster. In applications, gene / cell therapy development often represents the highest growth and value share segment, followed by vaccine development and synthetic biology. Among end users, academic & research institutions and biotech / pharmaceutical firms are major demand centers.
Recent Developments
Recent years have witnessed several notable developments and milestones in the gene synthesis market:
Some companies have announced or commercialized enzymatic synthesis platforms aimed at circumventing limitations of chemical methods (e.g. enabling longer sequences, lower waste, greener chemistry).
Partnerships and collaborations between gene synthesis providers and biotech / pharma firms (for e.g. antibody discovery, cell therapy development) have been formed to integrate design-synthesis-expression workflows more tightly.
Several vendors have introduced AI-driven sequence design tools that automatically optimize codon usage, minimize secondary structures, avoid problematic motifs, and integrate synthesis constraints.
Investment rounds and acquisitions: several firms have raised capital to scale next-generation synthesis technologies or extend global reach.
Regulatory and biosecurity enhancements: providers increasingly screen incoming orders for dangerous or regulated sequences, adding compliance and audit capabilities.
Platform scale-ups: vendors are building larger facilities, more automated synthesis lines, and geographic expansion (local labs or facilities in Asia, Europe, etc.) to reduce lead times and serve regional markets.
Service bundling: more firms now offer design + synthesis + delivery + assembly + validation packages, effectively becoming full-stack synthetic biology enablers.
Academic / public sector programs: national initiatives in synthetic biology and genomic engineering have increased funding and demand for high-throughput gene synthesis, especially in countries investing in biotech sovereignty.
These developments reinforce the view that the market is maturing toward a more integrated, technologically advanced, and globally distributed system.
Regional Analysis
The growth and dynamics of the gene synthesis market vary meaningfully across geographic regions, driven by research infrastructure, biotech maturity, regulatory environments, funding, and industry presence.
North America
North America, especially the United States, is currently the largest and most mature market. The region hosts many leading biotech firms, academic research institutions, gene therapy developers, and synthetic biology ventures. Strong funding, favorable regulatory climate, and early adoption of cutting-edge techniques underpin continued dominance. Many major players are headquartered here, and demand for custom gene synthesis, library design, and therapeutic constructs is high.
Europe
Europe is also a mature market with robust R&D infrastructure, strong pharmaceutical and biotechnological sectors, and supportive governmental policies for genomics and synthetic biology. Countries such as the UK, Germany, France, and Switzerland often act as hubs of innovation. Europe tends to be slower in regulatory uptake than the U.S. in some respects, but strong standards and oversight ensure high adoption of quality synthesis services.
Asia Pacific
Asia Pacific is projected to be the fastest-growing region over the forecast period. Countries like China, India, Japan, South Korea, Singapore, and Australia are rapidly building biotech ecosystems, investing heavily in synthetic biology, gene therapy, and agricultural biotech. As local capacities strengthen and costs fall, more research institutes and biotech firms in Asia will adopt gene synthesis. The geography also offers cost advantages, growing local demand, and potential for decentralized synthesis hubs. Many global providers are establishing facilities or partnerships in Asia to reduce lead times and serve regional clients.
Latin America
Latin America presents moderate growth potential. Several countries are expanding research capacity and biotech sectors (especially Brazil, Argentina, and Mexico). However, challenges like limited funding, regulatory complexity, and infrastructure constraints slow adoption. Over time, localized synthesis service providers and partnerships with global firms may drive increasing penetration.
Middle East & Africa
This region currently lags behind in gene synthesis adoption, but potential is emerging in countries investing in advanced biotech (e.g., Gulf states, South Africa). Constraints such as limited capital, fewer biotech firms, and regulatory gaps pose challenges. However, as regional R&D infrastructure develops and governments aim to build scientific capacity, opportunities for localized synthesis capabilities will grow.
Overall, while North America and Europe will contribute steady baseline demand, the major incremental growth — and volume expansion — is expected in Asia Pacific, Latin America, and select parts of the Middle East & Africa.
Browse To Related Article-
Rakuten Launches Minna no Ticket from NFT Marketplace
Top Fintech Innovations Transforming Japan’s Banking 2.0 Era
Neural Networks Explained: A Beginner’s Guide to AI and Deep Learning
What Are Autonomous Warehouse Robots? A Complete Guide for Modern Supply Chains
